NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

The deal had an effective date of April 2 and provides Warnex with C$300,000 (US$303,616) in cash proceeds. Under the transaction's terms, Neopharm assumes certain specific undisclosed liabilities related to the division. Subject to certain conditions, Warnex will have the right to terminate the lease for its Laval, Quebec facilities, which are owned by an affiliate of Neopharm, prior to the current expiry date of the lease.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.